Rohm and Haas Earns Best Paper Award during European Coatings Congress 2009
Rohm and Haas Earns Best Paper Award during European Coatings Congress 2009
Specialty materials company Rohm and Haas (NYSE:ROH) is pleased to announce that Dr. Zhenwen Fu, a distinguished scientist with the company’s Paint and Coatings Materials division, was awarded ‘Best Paper’ recognition during the 2009 European Coatings Show Congress held in Nürnberg, Germany. Dr. Fu’s paper presented findings related to a new diffusion technology in latex paint film formulations. In latex based coatings, volatile organic compounds (VOCs) are used as coalescents to ensure film formation. This new technology significantly improves early property development of waterborne latex coatings in a reduced, low VOC formulation that maintains coalescence performance to achieve required hardness, block, print and dirt pick-up resistance necessary for industrial coatings.
“Producing industrial coatings in reduced VOC latex paint formulations has been increasingly difficult to achieve while still meeting required environmental regulations,” said Dr. Fu. Designed Diffusion technology as advanced by Dr. Fu is a paradigm shift in film formulation that balances coatings properties through careful design of the polymer system and the selection of a coalescent package with unique partition coefficient and diffusion rate between different phases of the polymer system. This paper presents detailed evidence of this Designed Diffusion technology with analytical, physical and application data.
Dr. Fu has contributed to over 50 patents and publications in the areas of metal and semiconductor clusters, analytical method development and instrumentation, latex film formation, colloidal science, paper coatings and inkjet ink technology. He received a B.Sc. degree in Chemistry from Jilin University in Changchun, China and a Ph.D. degree in Physical Chemistry from the University of Utah in the United States.
To learn more about or other innovations in the European Region, visit us @ go.rohmhaas.com/coatings_eu
About Rohm and Haas Company
Rohm and Haas is a global pioneer developing innovative technologies and solutions for the specialty materials industry. Based in Philadelphia, PA, the company generated annual sales of approximately $9.6 billion in 2008. Visit www.rohmhaas.com for more information. imagine the possibilities™
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5930243&lang=en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Contact:
Laura Hadden
Rohm and Haas Director of Communications,
Specialty Materials
Phone: + 1 215-592-3054
E-mail: lhadden@rohmhaas.com
or
Rachel
Redshaw
European Communications Manager
Rohm and
Haas Paint and Coatings Materials
Phone: + 44 1829 770 353
Email:
rredshaw@rohmhaas.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bloom Announces Early 2026 UK Launch, Expanding into Europe with New Garden Pharma as Exclusive Manufacturer24.6.2025 07:05:00 CEST | Press release
The Bloom Brand, a recognized U.S. leader in cannabis vape, is making its international debut in the United Kingdom through an exclusive partnership with New Garden Pharma, a leading European EU-GMP cannabis operator. Together, the two companies will launch Bloom’s award-winning Classic and Live vape collections in the UK in Q1 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623573625/en/ This marks Bloom’s first international market expansion, as the company continues its global growth strategy with additional EU markets in development for 2026 and beyond. UK patients will gain access to Bloom’s superior formulations and proprietary hardware systems. For more than a decade, Bloom has built its reputation on delivering terpene-rich, flavor-forward strains paired with reliable technology. The brand has an established and leading presence across leading U.S. markets including California, Illinois, Florida, Michigan, Mi
ACI Worldwide Expands Technology Partnership Ecosystem to Power ACI Connetic24.6.2025 07:00:00 CEST | Press release
ACI’s unified cloud-based payments platform to boost operational resiliency and support increasing non-functional requirements of modern payment systems ACI Worldwide (NASDAQ:ACIW), an original innovator in global payments technology, has expanded its global technology partnership ecosystem to help financial institutions across the globe increase operational resiliency and address evolving regulatory requirements to safeguard the stability of the financial system. Building on strategic partnerships with Microsoft, Red Hat and IBM, ACI is collaborating with MongoDB, a document-oriented NoSQL database, and open source technology NATS from Synadia Communications for the reference architecture of ACI Connetic, ACI’s unified, cloud-native payments platform. These partnerships help extend ACI Connetic far beyond a traditional payments hub, delivering robust, highly functional payment engines to support financial institutions in meeting growingly stringent non-functional requirements and incr
Industrial 3-axis accelerometer has high offset stability24.6.2025 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has introduced a 3-axis accelerometer for the industrial market that combines high offset stability over temperature and time, good linearity, low noise density, and excellent robustness. The SCA3400-D01 XYZ accelerometer is meant for use in industrial applications such as structural health monitoring (SHM), machine control, inertial measurement units, and construction tools and systems. This product will be exhibited at Sensors Converge 2025 to be held at the Santa Clara Convention Center (Booth #716), California from 24 to 26 June 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623994075/en/ [Murata Manufacturing Co., Ltd.] Industrial 3-axis accelerometer The offset stability of an accelerometer refers to the consistency of its output when at rest, but subject to varying temperatures or the effects of aging. Ideally, this output should be zero, but i
Grid Dynamics Announces AI-Powered Engagement Model Enabling Accelerated Business Transformation for Fortune 1000 Enterprises23.6.2025 15:15:00 CEST | Press release
Key Takeaways: Grid Dynamics introduces an AI-powered engagement model for software delivery. This engagement model expands Grid Dynamics’ offerings by providing a fundamentally new way of delivering value—enabling clients to achieve superior outcomes by providing the next level of agility, quality, and accelerated time-to-market. The model is based on the Grid Dynamics AI-Native Development Framework (GAIN Development Framework)—a combination of proprietary processes, human capital, and an AI-Enabled Development Platform. This framework is designed specifically to support the scale and complexity of Fortune 1000 enterprises. Based on internal benchmarks, we expect this model to accelerate project delivery by achieving over 30% productivity improvements. Progressive credit-based pricing directly tied to performance and value is the basis of the new engagement model. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (Grid Dynamics)—a prominent technology consulting and digital services provid
Live Biotherapeutics at a Crossroad: Novotech White Paper Outlines Opportunities and Early-Stage Challenges23.6.2025 14:05:00 CEST | Press release
As Live Biotherapeutic Products (LBPs) begin to transition from frontier science to clinical reality, Novotech, a leading global CRO and scientific advisory partner has published a new white paper examining the opportunities and challenges shaping this fast-evolving landscape of therapeutic class. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623205345/en/ LBPs, which harness live microorganisms to restore or modulate human health, are being explored across a growing range of indications, from gastrointestinal and metabolic disorders to CNS and oncology. FDA approvals of Rebyota™ and Vowst™ have validated the category but for most biotech sponsors, the journey remains uncertain. According to Novotech’s analysis, over 90% of LBP assets are still in early development stages, and nearly one-third of all trials from 2020 to 2025 have been withdrawn or suspended due to regulatory, manufacturing, or design complexities. Highli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom